Delcath Systems DCTH CHEMOSAT — Product revenue

Other product segments

Similar metrics at other companies

GCTProduct revenues — Revenue

$290.82M+28.9%

ITRIProduct revenues — Revenue

$453.46M-12.3%

CORTHypercortisolism Products — Product revenue, net

$208.58M+7.3%

SNDXNet Product Revenues — Revenue

$31.21M+1,526%

QTRXProduct revenue — Total revenues

$23.48M+39.5%

WHDProduct revenue — Total revenues

$297.24M+42.2%

FAQ

What is Delcath Systems's CHEMOSAT — product revenue?

Delcath Systems (DCTH) reported CHEMOSAT — product revenue of $1.97M in Q2 2026.

How has Delcath Systems's CHEMOSAT — product revenue changed year-over-year?

Delcath Systems's CHEMOSAT — product revenue increased by 19.1% year-over-year, from $1.66M to $1.97M.

What is the long-term trend for Delcath Systems's CHEMOSAT — product revenue?

Over 2 years (2023 to 2025), Delcath Systems's CHEMOSAT — product revenue has grown at a 76.0% compound annual growth rate (CAGR), from $2.07M to $6.4M.

What does CHEMOSAT — product revenue mean?

This metric measures the total gross sales generated from the commercial distribution of a specific medical device or drug-device combination product within a defined reporting segment. It reflects the market adoption rate, pricing power, and commercial success of the product in treating its target patient demographic. Analyzing this revenue stream provides insight into the company's ability to transition from clinical development to sustainable commercialization and market penetration.